Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor VIII/von Willebrand factor - Grifols

Next Previous
Drug Profile

Factor VIII/von Willebrand factor - Grifols

Alternative Names: Alphanate; Fanhdi; Von Willebrand factor/Factor VIII

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Talecris Biotherapeutics
  • Developer Grifols
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 29 Jul 2016 Grifols initiates a phase II trial for Haemophilia A (In neonates, In infants, In children) in Spain (IV) (EudraCT2015-005524-26)
  • 23 Nov 2013 Grifols initiates enrolment in a phase IV postmarketing study for Von Willebrand's Disease (in paediatric patients with type I, II or III disease) in Spain (EudraCT2012-003450-92)
  • 14 Jan 2013 Launched for Haemophilia A in USA before January 2013 (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top